CM 355
Alternative Names: CM355; ICP-B02Latest Information Update: 17 Jun 2024
At a glance
- Originator InnoCare Pharma; KeyMed Biosciences
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II B-cell lymphoma